An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch

ENCePP Code of conduct

No

Data sources

• Data source(s):
  Clinical Practice Research Datalink
• Data sources (types):
  Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No